Psoriasis Clinical Trial

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

Summary

The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Plaque psoriasis involving up to 2 to 20% Body Surface Area

Exclusion Criteria:

Lesions solely involving intertriginous areas, the scalp or the face
Systemic therapy for their psoriasis
Pustular psoriasis or erythroderma
Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication
Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis
Receiving systemic triazole antifungals except fluconazole

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

199

Study ID:

NCT00778700

Recruitment Status:

Completed

Sponsor:

Incyte Corporation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Hot Springs Arkansas, , United States

Los Angeles California, , United States

San Diego California, , United States

Santa Monica California, , United States

Vallejo California, , United States

New Haven Connecticut, , United States

Miami Florida, , United States

Ormond Beach Florida, , United States

Naperville Illinois, , United States

Wheaton Illinois, , United States

Evansville Indiana, , United States

South Bend Indiana, , United States

Boston Massachusetts, , United States

Clinton Township Michigan, , United States

Fridley Minnesota, , United States

Saint Louis Missouri, , United States

Albuquerque New Mexico, , United States

Rochester New York, , United States

Norman Oklahoma, , United States

Simpsonville South Carolina, , United States

Austin Texas, , United States

College Station Texas, , United States

Dallas Texas, , United States

Houston Texas, , United States

Salt Lake City Utah, , United States

Norfolk Virginia, , United States

Walla Walla Washington, , United States

Madison Wisconsin, , United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

199

Study ID:

NCT00778700

Recruitment Status:

Completed

Sponsor:


Incyte Corporation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider